ALTER-DOMUS
19.7.2022 09:02:07 CEST | Business Wire | Press release
Alter Domus, a leading provider of integrated solutions for the alternative investment industry, today announced it has appointed Gus Harris, Head of AD Data & Analytics, to its Group Executive Board (GEB) where he will continue to report to Doug Hart, Chief Executive Officer.
In his current role, Gus leads Alter Domus’ data and analytics products strategy and team, developing new data assets and offerings to provide value-add solutions to alternatives market participants, including risk managers, investment managers, analysts and support functions at investor and asset manager clients. The team will help clients bring their data into a modern technology-enabled environment, allowing them to develop a competitive edge in their ability to efficiently generate meaningful and timely insights from their most crucial data sets.
As an extension to our data and analytics efforts, Gus is overseeing the development of proprietary applications into Software-as-a-Service (SaaS) products, which will further expand Alter Domus’ reach into the middle and front offices of their expanding client base. Early product development has focused on solutions which improve operational governance and efficiency for clients to more effectively risk-manage, monitor and grow their alternatives portfolios. The team has lined up several clients, including new clients, and strategic partnerships to accelerate their go-to-market and will have several newly built products by year-end.
Since joining Alter Domus last October, Gus has hired a world-class team to oversee the firm’s growth in this important area. The seasoned team, which has extensive experience building similar solutions for large financial institutions globally, brings together significant capabilities around modern big data, data science, technology, and product management disciplines. Team members have honed their skills at, and joined Alter Domus directly from, reputable institutions such as Amazon Web Services, Morgan Stanley, Moody’s Analytics, KPMG, and other established multinational organizations.
“Technology has been an integral part of the backbone of Alter Domus’ offering to clients, and Gus has brought an innovative and forward-thinking vision to our data and analytics services. Clients are under increasing pressure to better manage and exploit data, which makes Gus’ voice and perspective at a group executive level particularly important,” said Doug Hart . “Gus brings a strong sense of leadership, collegiality, and considerable expertise to our leadership team, key traits which have helped to catalyze his team’s growth and offering in a relatively short period of time.”
“I am proud to join Alter Domus’ group executive board, and I look forward to partnering with this talented and dynamic group of executive leaders. Alter Domus’ data and analytics team, which is comprised of seasoned and proven industry professionals, is undergoing tremendous growth and is already engaging with leading general and limited partners in the private equity, private debt – including CLO managers and investors – and commercial real estate sectors on complex and important projects,” said Gus Harris . “This reflects the increasingly important role that data and analytics will play in the future of our business, and the alternative investment industry as a whole. As the marketplace matures, demand for ‘better data’ will only continue to grow, and we are extremely well-positioned to support the market on this transformational journey. With technology running across the spectrum of our data solutions – from collection, to analytics, to delivery – we’re thrilled to be helping clients define the standards that will set their business on a solid foundation for sustainable future growth.”
Prior to joining Alter Domus in September 2021, Gus was a founding executive of Moody’s Analytics where he helped build several flagship products and services including Moody’s structured-finance products, ESG data and research services, Moody’s DataHub (DaaS), and other SaaS tools. Gus is a CPA and CFA charter holder and completed advanced degrees in finance from Columbia Business School, risk and statistics from New York University’s Stern School of Business, and technology from Pace University.
About Alter Domus
Alter Domus is a leading provider of integrated solutions, serving private equity, real assets and debt capital markets sectors with more than 3,600 employees across 36 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services. Find out more at www.alterDomus.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005226/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
